Neuronetics, Inc. (STIM) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $1.43. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is STIM = $8 (+459.4% upside).
Valuation: STIM trades at a trailing Price-to-Earnings (P/E) of -2.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.
Financials: revenue is $149M, +37.9%/yr average growth. Net income is $39M (loss), growing at -3.7%/yr. Net profit margin is -26.1% (negative). Gross margin is 48.5% (-27.8 pp trend).
Balance sheet: total debt is $90M against $22M equity (Debt-to-Equity (D/E) ratio 4.04, leveraged). Current ratio is 2.02 (strong liquidity). Debt-to-assets is 63.8%. Total assets: $142M.
Analyst outlook: 5 / 7 analysts rate STIM as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 36/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
